{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-22-000147","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.409572+00:00","generated_at":"2026-06-21T23:03:22.055137+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Salarius Pharma reports Q3 net loss $14.4M; seclidemstat trial paused on safety, FDA partial hold","bullets":["Q3 2022 net loss $14.4M ($6.41/diluted share) vs $3.7M ($2.09) in Q3 2021; includes $8.9M goodwill impairment.","Cash and equivalents $16.8M at Sep 30, 2022, down from $29.2M at Dec 31, 2021; cash runway into H2 2023.","Seclidemstat sarcoma trial on partial clinical hold after SUSAR; enrollment paused in both company and MD Anderson studies.","SP-3164 IND on track for H1 2023; favorable preclinical data presented at ASH abstract.","Nine-month net loss $25.2M ($12.13/share) vs $8.7M ($5.41) in prior period; operating cash burn $12.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-22-000147","json":"https://secwatch.observer/filing/0001615219-22-000147.json","markdown":"https://secwatch.observer/filing/0001615219-22-000147.md","text":"https://secwatch.observer/filing/0001615219-22-000147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/0001615219-22-000147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/flks-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:03:22.055137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1807ff629d5ad1910bbd5bd06a4cc4c6ee75eb34","claim":"Decoy Therapeutics Inc. reported three and nine months ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share, EPS $6.41 per share.","evidence_excerpt":"Salarius Pharmaceuticals, Inc. (the “Company”) reported financial results for the three and nine months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/0001615219-22-000147-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2022"},{"label":"Net income","value":"Net loss for the third quarter of 2022 was $14.4 million, or $6.41 per share"},{"label":"EPS","value":"$6.41 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}